We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 228

Formulation patent found not to be infringed as a redacted excipient was not a “pentahydric or hexahydric alcohol”
  • Borden Ladner Gervais LLP
  • Canada
  • April 22 2015

Apotex has successfully alleged that Teva’s patent to “Stable Compositions Containing Rasagiline” will not be infringed by Apotex’s use of a


Court grants judicial review of minister of health’s decision
  • Borden Ladner Gervais LLP
  • Canada
  • January 16 2014

Apotex brought this application for judicial review of a decision of the Therapeutic Products Directorate (TPD) refusing to review Apotex’


Astrazeneca Canada Inc. v. Apotex Inc., 2015 FC 671
  • Borden Ladner Gervais LLP
  • Canada
  • July 7 2015

The parties moved under Rule 397 to modify the terms of the judgment in the proceeding, previously reported as 2015 FC 322 and summarized in our


Purdue Pharma v. Canada (Minister of Health)
  • Borden Ladner Gervais LLP
  • Canada
  • July 26 2010

The Court dismissed an application for judicial review of the Minister of Health's decision refusing to list a patent on the Patent Register


Finding of "fair expectation of success" leads to finding of obviousness
  • Borden Ladner Gervais LLP
  • Canada
  • March 11 2013

Teva sent two Notices of Allegation, one in respect of 50mg tablets and the second in respect of 150, 200, 300 and 400mg tablets, which were addressed


Patent held invalid for not meeting promise of improved therapeutic profile
  • Borden Ladner Gervais LLP
  • Canada
  • July 10 2014

Apotex was successful in the previous NOC Proceeding. It came to market with an esomeprazole product. AstraZeneca sued for patent infringement and


Court grants motion to reopen trial and admit new evidence
  • Borden Ladner Gervais LLP
  • Canada
  • April 27 2011

The Federal Court granted leave to reopen the trial and admit new evidence in a matter under reserve, in which no reasons or judgement have issued


Patent Appeal Board has jurisdiction to consider new defects introduced by the applicants amendments made in response to a final action
  • Borden Ladner Gervais LLP
  • Canada
  • March 26 2012

The application relates to a dual balloon catheter


Merck leave to appeal to SCC dismissed
  • Borden Ladner Gervais LLP
  • Canada
  • June 18 2012

The Supreme Court of Canada dismissed Merck’s application for leave to appeal, with costs to Apotex


Pleadings for disgorgement of profits and for an accounting of profits in s.8 damages not struck in Ontario court
  • Borden Ladner Gervais LLP
  • Canada
  • August 1 2012

In this case, Apotex has claimed damages in Ontario Court pursuant to, inter alia, section 8 of the NOC Regulations. Lilly brought a motion to strike out parts of Apotex’ statement of claim